Bristol Myers Squibb Company $BMY Shares Newly Purchased by New England Research & Management Inc.

New England Research & Management Inc. acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 31,175 shares of the biopharmaceutical company’s stock, valued at approximately $1,945,000.

A number of other large investors also recently modified their holdings of the company. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb during the second quarter valued at approximately $27,000. Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $32,000. Bayban bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $31,000. Groupe la Francaise lifted its holdings in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 501 shares during the last quarter. Finally, Kilter Group LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BMY has been the subject of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a research note on Wednesday, September 16th. Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 target price on shares of Bristol Myers Squibb in a research report on Monday. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Rothschild & Co Redburn boosted their price target on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group upgraded shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $64.88.

Bristol Myers Squibb Trading Down 1.4%

Bristol Myers Squibb stock traded down $0.88 during trading hours on Friday, reaching $59.69. The company had a trading volume of 13,770,205 shares, compared to its average volume of 14,832,782. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a 50-day moving average price of $63.55 and a 200 day moving average price of $60.29. The firm has a market cap of $121.94 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.